Abstract Library

#2094 Disease Control in Progressive Pancreatic and Intestinal Neuroendocrine Tumors by Combined Treatment with Lanreotide Autogel and Temozolomide: The SONNET Study

Introduction: In advanced NETs antiproliferative treatment options beyond somatostatin analogues remain limited. Temozolomide (TMZ) has shown efficacy in NETs alone or combined with other drugs.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Pavel M, Denecke T, Lahner H, Hörsch D, Rinke A,

Keywords: lanreotide, temozolomide, somatostatin analogues, combination therapy, progressive advanced NET, SONNET,

#1795 Results from a Phase 2, Open-Label, Multicenter, Randomized Study of the Novel, Octreotide (Oct) Subcutaneous (SC) Depot Formulation in Patients with Functioning Neuroendocrine Tumors (NETs) and Acromegaly Previously Treated with Long-Acting Octreotide

Introduction: Oct sc depot is a novel, ready to use formulation administered via a thin needle.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Pavel M, Borson-Chazot , Hörsch D, Lahner , Pivonello R,

Keywords: octreotide sc depot, NET,

#1554 Combination of Lanreotide Autogel and Temozolomide in Patients with Progressive Gastro-entero-pancreatic Neuroendocrine Tumours (GEP-NET) - A Pilot-Study

Introduction: Therapeutic options for patients with advanced progressive GEP-NET are still limited.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Raderer M

Authors: Raderer M, Hörsch D, Lahner H, Rinke A, Denecke T,

Keywords: GEP-NET, Lanreotide, Temozolomide,

#1495 Everolimus for Advanced, Progressive, Nonfunctional Neuroendocrine Tumors (NET) of the Gastrointestinal (GI) Tract: Efficacy and Safety from a RADIANT-4 Subgroup Analysis

Introduction: Everolimus (EVE) demonstrated progression-free survival (PFS) benefit of 7.1 months compared to placebo in the phase 3 RADIANT-4 study in patients (pts) with advanced, well-differentiated, progressive, nonfunctional NET.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Singh S

Authors: Singh S, Carnaghi C, Buzzoni R, Raderer M, Lahner H,

Keywords: Everolimus, progression-free survival, gastrointestinal NET,

#1205 Temozolomid-Based Therapy in GEP-and Bronchopulmonary NEN from a Multicentric Study from Germany

Introduction: Chemotherapy (CTx) with temozolomid as mono (TEM) or combination therapy with capcitabine (TEM/CAP) is a new cytotoxic regimen with good efficiency in pancreatic and bronchopulmonary NET-G1/G2 and NEC-G3.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Maasberg S, Bacher M, Rinke A, Lahner H, Unger N,

Keywords: temozolomide, capecitabine,